X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

Research And Development In UK Falls Behind Other Nations

Content Team by Content Team
28th October 2022
in News, Research & Development
As Medical Uses Cope Up, Genomic Studies Reap Scale Benefits

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

According to a new report by IPPR, the UK’s percentage of worldwide research and development (R&D) spending has decreased by 5% since 2014. Even while successive prime leaders, from David Cameron’s jewel in the crown to Boris Johnson’s science superpower, have emphasised research and innovation as a key component of their growth policies, the decline, from 4.2% to 3.4%, has occurred.

In terms of total R&D spending as a proportion of GDP, the UK only ranks 11th, well behind nations like Austria, Switzerland, and the US. The amount invested in global R&D by the UK in 2014 would have increased by £18 billion, or 26%, in 2019. According to IPPR research, in order to surpass Israel as the leader in R&D spending this year, the UK will need to invest an extra £62 billion from both the public and private sectors.

IPPR’s additional modelling shows that public investment stimulates private sector investment. For instance, private investors would contribute an additional £1.36 billion over ten years, for instance, if the UK government committed £1 billion more on research and development. According to the Organization for Economic Co-operation and Development ranking for luring foreign private investment, the UK is now ranked 34th out of 36 countries.

The Institute contends that spending money on health sciences is far more effective than cutting company taxes if the government intends to adopt a growth goal. The bio sciences sector is the one that invests the most in R&D worldwide.

Although official estimates of public and corporate R&D expenditure have increased significantly as a result of modifications in the Office for National Statistics (ONS) methodology, the UK still lags far behind other developed nations.

With the amended technique, the UK has officially achieved the government’s goal of investing 2.4% of GDP in R&D, albeit more by accident than by design. To combat the UK’s persistent lack of growth and low productivity, the Institute for Public Policy Research (IPPR) contends that significant increased R&D investment is essential.

The IPPR advises the government to adopt a new, ambitious R&D goal right away. Three possible trajectories that have been modelled by researchers are as follows:

As per the report’s findings, investing in R&D might particularly benefit the field of health research. The UK requires a mission-based strategy for life sciences policy, much like the US government’s goal of landing a man on the moon in the 1960s. As a result, activity would be more in line with broader social objectives, a coherent sense of strategic vision would be communicated, and new investment would crowd in, increasing funding for R&D.

According to IPPR economist and report author Shreya Nanda, R&D and the life sciences were the fuel that drove tremendous advancements in human health and national prosperity in the 20th century. The COVID-19 vaccine serves as a reminder of science’s ongoing, transformational promise in the twenty-first century. The UK is falling behind, though, whether in ground-breaking research for future technology or life-saving medications.

Previous Post

FDA Under Strain To Amend The Accelerated Approval Program

Next Post

CPHI Report Says, Biologics Outsourcing Will Surge In 2023

Related Posts

WuXi Biologics and Virogen Bio partner to advance VG712
News

WuXi Biologics and Virogen Bio partner to advance VG712

19th June 2025
Construction of WuXi Biologics Microbial Manufacturing Site
News

Construction of WuXi Biologics Microbial Manufacturing Site

19th June 2025
Beyfortus From Sanofi to Make Imprint in 2025 26 RSV Season
News

Beyfortus From Sanofi to Make Imprint in 2025-26 RSV Season

19th June 2025
Thermo-Fischer-Accelerator Drug Development an Ideal Choice
News

Thermo Fischer Accelerator Drug Development an Ideal Choice

19th June 2025
IQVIA Custom Built AI Agents for Life Sciences Healthcare
News

IQVIA Custom-Built AI Agents for Life Sciences, Healthcare

19th June 2025
SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Next Post
CPHI Report Says, Biologics Outsourcing Will Surge In 2023

CPHI Report Says, Biologics Outsourcing Will Surge In 2023

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In